Specialty Pharmacy

Patients who were more satisfied with the communication they received from cancer care providers often had better health outcomes at lower costs.

Researchers have developed a novel peptide drug that has the potential to reduce tumor growth and slow down the spread of cancer cells.

Top news of the day from across the health care landscape.

Treating patients’ stress and poor sleep may help reduce the risk of depression in multiple sclerosis.

A phase 1 trial evaluating the safety and tolerability of PRN2246, a Bruton's tyrosine kinase (BTK) inhibitor, found the drug having no serious medication-related adverse events in healthy volunteers while also being able to reach the brain.

The 2018-19 Best Hospital’s Honor Roll is a distinction awarded to 20 hospitals delivering exceptional treatment across multiple areas of care.

Globally, lung cancer mortality rates among women are projected to increase by 43% from 2015 to 2030.

Botox injections found to decrease urinary incontinence and improve quality of life for patients with multiple sclerosis.

Organ transplant recipients who received infected kidneys were cured of hepatitis C after taking antiviral therapy following the procedure.

Top news of the day from across the health care landscape.

Migalastat (Galafold, Amicus Therapeutics) is the first oral medication for the treatment of adults with Fabry disease, a rare genetic disorder.

Midazolam Nasal Spray—from global biopharmaceutical company UCB, Brussels, Belgium (UCB)—has been previously granted Orphan Drug and Fast Track designations by the FDA

The annual cost of treating cancer is projected to rise to $173 billion by 2020, a 39% increase since 2010.

The guidelines fill an unmet clinical need for a standard care consensus on gestational trophoblastic neoplasia, a group of rare cancers that affect pregnant women.

Top news of the day from across the health care landscape.

Jesse C. Dresser, JD, Partner, Frier & Levitt, LLC, speaks about the regulation of pharmacy benefit managers and how it can impact specialty pharmacy operations.

Pharmacy benefit manager says it retained approximately $300 million in drug rebates, well under the $2 billion amount that some projected.

Patisiran (Onpattro, Alnylam Pharmaceuticals) is indicated for the treatment of adult patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR), a rare genetic disease.

In response to the CMS’ step therapy approach to lowering drug costs, many advocacy groups expressed concern that the move will harm patient access to treatments for chronic conditions.

Higher-than-recommended physical activity levels can help older adults avoid chronic diseases, disability, and cognitive decline for longer.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

A protein that regulates the formation of myelin sheaths may lead to new treatments for multiple sclerosis.

American Medical Association urges the Department of Justice to block merger between CVS Health and Aetna due to concerns over anticompetitive practices in health care market.

Drug costs in the United States are not consistently associated with their value or net health benefits.

Top news of the day from across the health care landscape.

Study offers insight into the evolution of global dissemination of hepatitis B virus genotypes D and A.

In this clip, Patricia Kienle, BSPharm, MPA, FASHP, Director of Accreditation and Medication Safety at Cardinal Health Innovative Delivery Solutions, discusses key steps for performing an assessment of risk in compliance with USP 800.

The revised labeling for glecaprevir and pibrentasvir (Mavyret) includes data from clinical trials on the safety and efficacy of the treatment for HIV-1 coinfected patients and liver and kidney transplant recipients.